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Summary Monoclonal antibodies 19-9 and C-50 were used to assay the cancer associated tumour antigens
CA 19-9 and CA-50 in plasma from patients with confirmed pancreatic cancer, and related to the blood group
and Lewis blood cell status. The plasma expressions of CA 19-9 or CA-50 were similar, including cases where
the patients had Lewis phenotype Le (a - b -). However, analyses of both the tumour antigens could be used
to differentiate the presence of cancer from its absence in Le (a - b -) individuals. The findings indicate that
the targets for the monoclonal antibodies 19-9 and C-50 are similar. The practical implications of these
findings are discussed.
The Lewis antigens are not integral parts of the red cell
membrane but are absorbed onto the cell membrane from
plasma (Grubb, 1951; Makela et al., 1967). The genes of the
A, B, 0, Hh, Lewis and secretor (Se) systems are intimately
related in the production of the A, B, H, Lea and Leb
substances found in body fluids. These substances are glyco-
proteins or glycolipids composed of approximately 80% car-
bohydrate and 15% amino acids with an average molecular
weight of 300,000 (Kabat, 1956; Watkins, 1966). The oligo-
saccharide chains contain predominantly D-galactose (Gal),
N-acetylgalactosamine (GalNAc), L-fucose (fuc), and N-ace-
tylglucosamine (GlcNAc). The blood group specificity resides
on the terminal non-reducing sugar residue. The linkage of
this sugar to the penultimate sugar gives either a type 1 chain
(p 1-3 linkage) or a type 2 chain (p 1-4 linkage). The
addition of fucose to the non-reducing galactose and the
penultimate GlcNAc gives the blood group substances H,
Lea, Leb, X (Lex) and Y (Ley). The structures of these
substances are shown in Figure 1.
Antigen
H-I
H-II
Lea
Structure
Gal 1l-3GlcNAc p1-3Gal P1-4 Glc -R
jal,2
Fuc
Gal p1-4GlcNAc P1-3Gal P1-4 Glc -R
jal,2
Fuc
Gal p1-3GlcNAc 01-3Gal /1-4 Glc -R
jal,4
Fuc
Leb Gal pl-3GlcNAc 01-3Gal 11-4 Glc -R
cal,2 Ial,4
Fuc Fuc
The genes of the Lewis system are Le and le. The presence
of either heterozygous (Lele) or homozygous alleles (LeLe)
produces Lea substance, giving the red cell and mucin pheno-
type Le (a + b -). In individuals who have inherited H and
Se genes, most of the Lea substance is converted to Leb,
giving the phenotype Le (a - b + ). The simultaneous pre-
sence of two fucose residues on the type 1 chain results in an
almost complete loss of Lea activity. The phenotype Le
(a - b -) is obtained with homozygous lele alleles (Marr et
al., 1967; Watkins & Morgan, 1959).
Interest in the Lewis substances arises from the fact that
oncogenic transformation of mucin producing cells often
results in the expression and release into circulation of com-
plex carbohydrates whose structures are based on or closely
related to the Lewis substances. The recognition of these
structures by monoclonal antibodies (mabs) such as 19-9 and
CA-50 forms the basis for their use as tumour markers.
These mabs were derived by immunising mice with colorectal
adenocarcinoma cell lines (Koprowski et al., 1979; Lindholm
et al., 1983). Mab 19-9 was claimed to react specifically with
molecules containing a sialylated Lea structure in their non-
reducing end (Figure 2), lacking in 7-10% of the population
with the Lewis phenotype Le (a - b -) (Magnani et al.,
1981, 1982; Kabat, 1956; Dienst et al., 1987). This limits the
clinical use of CA 19-9. The simultaneous presence of both
N-acetylneuraminic acid (NANA) and fucose was shown to
be necessary for the binding of this antibody to the antigen
(Magnani et al., 1982). The mab C-50 was found to react
with the same antigenic determinant as 19-9 and an addi-
tional antigen in which the fucose residue linked to GlcNAc
(Figure 2) is absent (Nilsson et al., 1985; Mansson et al.,
1985). Hence, the mab C-50 is said to be reactive even in
cases where the patients are Le (a - b -) phenotypes.
Both these mabs are available in commercial kits for in
vitro diagnostic purposes, and are reported to have good
specificity and sensitivity for exocrine pancreatic cancer (Di-
enst et al., 1987; Heptner et al., 1986; Haglund et al., 1987;
Masson et al., 1988). The main purpose of this study was to
X (Lex)
Y (Ley)
Gal p1-4GlcNAc P1-3Gal 31-4 Glc -R
cal,3
Fuc
Gal /l-4GlcNAc pl-3Gal P1-4 Glc -R
ICjl,2 jal,3
Fuc Fuc
Antigen
SLNF II a)
SLNTa b)
Figure 1 Structures of H and Lewis blood group substances.
R = Ceramide or protein.
Gal P1-3 GlcNAc P1-3 Gal /1-4 Glc -R
1a2,3 jal,4
NANA Fuc
Gal 31-3 GlcNAc /1-3 Gal 31-4 Glc -R
ja2,3
NANA
Figure 2 Structures of mabs 19-9 and C-50 reactive antigens. a,
Mabs 19-9 and C-50 reactive. SLNF II = sialyl lacto-N-fuco-
pentaose 11. NANA = N-acetylneuraminic acid. b, C-50 reactive.
SLNTa = Sialyl lacto-N-tetraose.
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assess these mabs in plasma from patients with pancreatic
cancer with respect to the A, B, 0 blood group and Lewis
status of the patients.
Materials and methods
Blood samples for serology and Lewis phenotyping and
plasma for the tumour markers were collected from patients
remitted to the Department of Surgery for suspicion of
malignancy (based on anamnesis and clinical observations
such as weight loss, jaundice, etc.). Pancreatic cancer was
confirmed in 67 patients partly on the basis of clinical and
radiological findings (CT, NMR, ultrasonography and/or
autopsy) and partly on verification by histology on samples
obtained during laparotomy, autopsy or by aspiration
cytology on all but seven patients. Lewis phenotyping was
also performed in the saliva collected from six patients whose
red cell phenotype was Le (a - b -). Twenty-two patients
found to be free from cancer of the pancreas after thorough
examination were included in this study as a control group
because they had Le (a - b - ) phenotype. The plasma sam-
ples were stored at - 20°C until analysed. CA 19-9 was
analysed using Elsa CA 19-9 kit (CIS Bioindustries, Oris,
France) and CA-50 using CanAg CA-50 IRMA test (Phar-
macia CanAg, Gothenburg, Sweden). The analyses in each
case were performed according to the manufacturer's instruc-
tions. Blood group and Lewis phenotyping was performed at
the Department of Blood Transfusion, University Hospital of
Lund. Where appropriate, the results were evaluated using
Spearman rank correlation, Mann-Whitney correlation and
x2 analyses.
Results
The frequency distribution of the Lewis phenotypes in the
patients with pancreatic cancer is shown in Figure 3, where
one patient (2%) was classified as Le (a + b + ), 11 patients
(17%) as Le (a + b-), 43 patients (64%) as Le (a-b + )
and 12 patients (18%) as Le (a - b -). The frequency for Le
(a - b -) was compared to the published frequencies using
the x2 test. A significant difference was found compared to
the reported frequency of 7% (P = 0.019), but no difference
was evident when compared to the frequency of 10%
(P = 0.086). The Lewis phenotype of the six patients where
blood and saliva were tested was the same (Le (a - b -)).
The blood groups for each group are shown in Table I. The
three-dimensional frequency histogram for tumour antigen
concentrations upto 25,000 u ml-' are shown in Figure 4,
showing an almost identical distribution for CA 19-9 and
CA-50. Furthermore, the tumour markers were compared to
each other using Spearman correlation test. The correlations
between CA 19-9 and CA-50 were high both in the case of
patients with pancreatic cancer (r = 0.88, P = 0.000, n = 67)
and in the total patient material (r = 0.90, P= 0.000, n = 89).
Four of the patients with pancreatic cancer had concentra-
tions higher than 25,000 u ml- ', two of these were Lewis
phenotype Le (a - b + ) and two were Le (a - b -). The
highest concentration for CA 19-9 (270,000 u ml-') was
found in a patient with Lewis phenotype Le (a - b -). The
patient with the Lewis phenotype (a + b + ) had concentra-
tions of 450 u ml-', for each tumour marker.
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Figure 3 Frequency histogram of Lewis status in the blood of
patients with pancreatic cancer (n = 67).
The mean values, medians and standard deviations for CA
19-9 and CA-50 for the three Lewis phenotypes (excluding Le
(a + b + )) and non-pancreatic cancer patients are shown in
Table II. Although the mean values and the medians for
CA-50 and CA 19-9 in patients with pancreatic cancer differ
slightly from each other in the group Le (a + b -), more in
the group Le (a-b + ) and most in Le (a-b-), these
differences are not statistically significant (Mann-Whitney
correlation test).
The presence or absence of pancreatic cancer seemed to be
of more importance and the differences in the median value
either for CA 19-9 or CA-50 concentrations in the pancreatic
cancer patients with Lewis phenotype Le (a - b -) differed
significantly from the corresponding values for the patients
without pancreatic cancer with the same Lewis phenotype
(P = 0.005 for CA 19-9 and 0.035 for CA-50 using Mann
-Whitney test). This should be assessed against the back-
ground that these patients had the same symptoms as the
patients with pancreatic cancer (loss of weight, jaundice, etc.)
at the time of blood sampling and were investigated due to a
strong clinical suspicion of cancer.
Discussion
The Lewis phenotype distribution showed the presence of
one patient with Le (a + b + ) in our material. This has been
reported before but the normal frequency of the phenotype is
very low (in the order of 1:10000). The normal distribution
of the red cell phenotypes Le (a + b - ), Le (a - b + ) and Le
(a - b -) in a Caucasian population has been reported in
textbooks as 20, 73 and 7%, respectively (Kabat, 1956). The
frequency of Le (a - b- ) has also been reported to be as
high as 10% (Dienst et al., 1987). Statistical evaluation of the
frequency observed by us showed that it differed from 7%
but not 10%. We feel that the patient material in our study is
Table I Blood groups of the patients
l b hC d
Bloodi grolip Le (a+hb-) Le (a-h+ ) Le (a-b-) Le (a-b-)
A 6 23 8 16
B 2 6 0 2
AB I 1 1 I
0 2 13 3 3
Groups a c: patients with pancreatic cancer. Group d: without pancreatic cancer.120 P. MASSON et al.
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Figure 4 Three-dimensional frequency histogram. The concen-
trations of CA 19-9 (a) or CA-50 (b) vs Lewis status, where
I = Le (a + b +), 2 = Le (a + b-), 3 = Le (a- b +) and 4= Le
(a - b - ).
limited to permit any definite conclusions regarding these
differences to be drawn.
The distribution of the A, B, 0 blood groups was as
expected and showed no correlation to the values either of
CA 19-9 or CA-50. The similarities in the frequency distribu-
tion of CA 19-9 and CA-50 in the different Lewis groups,
even in the case Le (a - b -), show that the mab 19-9 reacts
even in these patients, where one would not expect synthesis
of the antigenic determinant. There are some possible reasons
for these discrepancies. First, mab 19-9 has a specificity
which is broader than that reported. Bearing in mind that the
presence of both sialic acid and fucose are necessary for the
reactivity, there are two possible structures where the sialic
acid can be present, namely on the Lea and the X antigen.
Since the reactivity of the mab against structures with type 2
chain (p 1-4 linkage to the penultimate GlcNAc) is approx-
imately 100 times less than analogous structures with type 1
chain (p 1-3 linkage), the sialylated X antigen needs to be
produced in much higher concentrations to give appreciable
responses (Masson et al., 1989).
A recent study has shown that the carbohydrate chains
having blood group ABH determinants are mainly composed
of type 2 chains and that both Lea and X substances are
present in human red blood cells as glycolipids irrespective of
blood group ABH status (Kannagi et al., 1985). Hetero-
geneity in the co-expression of Lea and X (LeX) together with
the other antigens Leb and Y (Ley) has been shown in
patients with pancreatic cancer, although it was surprising
that individuals with Lewis phenotype Le (a - b -) did not
react with CA 19-9 mab (Kannagi et al., 1985; Pour et al.,
1988).
Another possibility is that individuals whose red cell pheno-
type is Le (a - b -) may still be able to produce Lea
substances in the tumours as a result of oncogenic transfor-
mation. This activates a 1,4 fucosyl transferase responsible
for the addition of fucose on a type 1 carbohydrate chain.
Such transformations have been speculated since individuals
with pancreatic cancer and blood cell phenotype Le
(a - b -), were shown to have Lea substance in their serum
and saliva (Yazawa et al., 1988). Although our study showed
that the same Lewis phenotypes were obtained in blood and
saliva, the possibility of the presence of Lea substances deriv-
ing from the tumour cannot be excluded.
The histological distribution of CA 19-9 and CA-50 in
pancreatic tissues appear either to be similar, or differs slight-
ly. However, no reaction has been seen for CA 19-9 in
patients with Lewis phenotypes Le (a - b -) and the reac-
tion for CA-50 has been weak (Haglund et al., 1986;
Schwenk & Makovitzksy, 1989). This is expected in view of
the fact that C-50 mab also recognises sialylated lacto-N-
tetraose structure. These results differ from our findings that
the reaction of the mab 19-9 does not seem to depend on the
Lewis status. It is feasible that the preparation of the tissue
for histological studies results in the loss of the glycolipid as
well as part of the glycoprotein antigens giving either a weak
or no response in some cases.
Finally, in view of the structural complexities and hetero-
geneity of the carbohydrate structures, it is equally feasible
that both the 19-9 and C-50 mabs react with determinants
either larger in size or more heterogeneous than the ones
described. This has to be further evaluated.
In conclusion, we have found no difference in the plasma
expression of CA 19-9 and CA-50 in patients with pancreatic
cancer with respect either to the A, B, 0 blood groups or to
the Lewis status, even in those with the Lewis phenotype Le
(a - b -). However, the presence or absence of cancer cor-
related well with the plasma concentrations either of CA 19-9
or of CA-50 in Le (a - b -) patients. Bearing in mind that
the main use of the tumour markers is in supporting diag-
nosis once the clinical examination indicates strong suspicion
of pancreatic cancer, rather than a primary diagnostic tool, it
appears that CA 19-9 can also be used without prior know-
ledge of the Lewis phenotype of the patient. However, this
knowledge may serve a vital function in the use of the
tumour marker to detect recurrence in Le (a - b -) individ-
uals. Such an observation can provide further evidence for
Table II Summary statistics
a b c d
Le (a+b-) Le (a-b+) Le (a-b-) Le (a-b-)
n 11 43 12 22
Mean (u ml')
CA-50 1247 5367 4346 384
CA19-9 807 7232 28465 397
Median (uml')
CA-50 300 250 273 45
CA 19-9 311 310 605 30
Standard deviation (umlh')
CA-50 2043 18803 9466 912
CA 19-9 879 25038 77537 1092
Groups a-c: patients with pancreatic cancer. Group d: without pancreatic cancer.CA 19-9 AND CA-50 IN PANCREATIC CANCER 121
the hypothesis that oncogenic transformation in most, if not
all of these individuals is associated with the activation of a
1,4 fucosyl and other transferases.
We are grateful to Ann-Cathrine Lofstrom for excellent technical
assistance. This work was partly supported by grants from the
Medical faculty, University of Lund.
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